September 20, 2022 02:32 PM EDT
Pharma
Law

Un­sealed doc­u­ments de­tail Bio­gen's fight against San­doz Tysabri biosim­i­lar

Nicole DeFeudis

Editor

San­doz is hop­ing to cel­e­brate its re­cent­ly an­nounced spin­off from No­var­tis with swift ap­provals for its Tysabri biosim­i­lar in both the US and Eu­rope …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

Can the Pfiz­er ma­chine fight back against an ac­tivist in­vestor?

HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

Charles Riv­er dis­ap­points in­vestors with damp out­look for 2025

Lykos up­heaval con­tin­ues with four new board ex­its amid hunt for cash

A service from the Financial Times